Press Releases

CRANBURY, N.J., Sept. 21, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that the Company and Gedeon Richter (Richter) mutually and amicably agreed to terminate the license and collaboration agreement for bremelanotide […]

CRANBURY, N.J., Sept. 16, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter, fiscal year end 2015 operating results on Monday, September 21, 2015 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on

CRANBURY, N.J., Aug. 18, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential. Palatin’s lead product under development is bremelanotide for the treatment of female sexual dysfunction (FSD). The approval of flibanserin (under development

CRANBURY, N.J. and FARMINGTON, Conn., July 6, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that it has closed on a private placement of Series E warrants to purchase 21,917,808 shares of

CRANBURY, N.J., June 4, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) – Today’s FDA Advisory Committee’s recommendation for the approval of flibanserin is an important step forward in women’s health, as the decision addresses the important need for the women living with hypoactive sexual desire disorder, or HSDD, to have an approved treatment option.

CRANBURY, N.J., May 13, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2015.  Recent Highlights Launched reconnectstudy.com in support of our Bremelanotide Phase 3

CRANBURY, N.J., May 8, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2015 operating results on Wednesday, May 13, 2015 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May

CRANBURY, N.J., March 6, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that it will be presenting at the 27th Annual ROTH Conference on Wednesday, March 11, 2015, at 10:30 a.m. Pacific Time.  The conference will be held at the Ritz Carlton Laguna Niguel in Dana Point, CA. Carl Spana, Ph.D., President and

CRANBURY, N.J., Feb. 20, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has launched a clinical trial website (https://www.reconnectstudy.com) in support of its phase 3 reconnect study with bremelanotide for

CRANBURY, N.J., Feb. 13, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2014.  “We achieved a significant clinical and corporate milestone by advancing bremelanotide